The information on this site is provided by CodeMap®. CodeMap® remains solely responsible for its content. The information provided is for general educational purposes only and may not be conclusive or exhaustive. Recent changes in applicable law, regulations and interpretations may not be reflected in the information contained herein. For technical questions, please contact CodeMap. This website is a private website and is not associated, endorsed or authorized by the Department of Health and Human Services, the Center for Medicare and Medicaid Services or any other public or government organization or agency. Healthcare-Associated Infections Enteric Infections Women's Health & Sexually-Transmitted Infections COVID-19 Point of Care Please select your state:NATIONAL LIMIT National Limits ALABAMA ALASKA ARIZONA ARKANSAS CALIFORNIA COLORADO CONNECTICUT DELAWARE DIST of COL-DC + MD/VA Suburbs FLORIDA GEORGIA HAWAII IDAHO ILLINOIS INDIANA IOWA KANSAS KENTUCKY LOUISIANA MAINE MARYLAND MASSACHUSETTS MICHIGAN MINNESOTA MISSISSIPPI MISSOURI MONTANA NATIONAL LIMIT NEBRASKA NEVADA NEW HAMPSHIRE NEW JERSEY NEW MEXICO NEW YORK NORTH CAROLINA NORTH DAKOTA OHIO OKLAHOMA OREGON PENNSYLVANIA PUERTO RICO RHODE ISLAND SOUTH CAROLINA SOUTH DAKOTA TENNESSEE TEXAS UTAH VERMONT VIRGINIA WASHINGTON WEST VIRGINIA WISCONSIN WYOMING Fees Reflect 2025 CMS Medicare Fee Schedules Fee schedules do not reflect 2% Payment Adjustment (Sequestration). Click here for more information. BD MAX™ SYSTEM Redefine staff productivity with a fully-integrated, automated molecular platform capable of running both IVD and open system assays efficiently and flexibly. BD MAX™ Individual Assays CPT® Code Description Medicare Coverage NATIONAL LIMIT Medicare Reimbursement NATIONAL LIMIT Medicaid Reimbursement BD Vaginal Panel for BD MAX™ and/or BD COR™ System   81514 Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei, when reported   CCI   MUE   $262.99 N/A BD CTGCTV2 on the BD MAX™ and/or BD COR™ System Detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis.   87491 * Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique   CCI   MUE   NCD $ 35.09 (Individual test) N/A (Individual test)   87591 * Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique   CCI   MUE   NCD $ 35.09 (Individual test) N/A (Individual test)   87661 Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique   CCI   MUE   $ 35.09 (Individual test) N/A (Individual test) * use -59 modifier with this code when ordered with the BD MAX Vaginal Panel Total Reimbursement: $105.27 $0.00 BD MAX™ GBS Group B Streptococcus (GBS) DNA in Lim broth cultures obtained from vaginal-rectal swab specimens from antepartum pregnant women.   87150 Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed   CCI   MUE   $ 35.09 N/A   87081 Culture, presumptive, pathogenic organisms, screening only;   CCI   MUE   $ 6.63 N/A BD Affirm™ VPIII Includes 3 targets: Gardnerella vaginalis, Candida species, and Trichomonas vaginalis. Candida species   87480 Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique   CCI   MUE   $ 20.05 (Individual test) N/A (Individual test) Gardnerella vaginalis   87510 Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, direct probe technique   CCI   MUE   $ 20.05 (Individual test) N/A (Individual test) Trichomonas vaginalis   87660 Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, direct probe technique   CCI   MUE   $ 20.05 (Individual test) N/A (Individual test) Total Reimbursement for Panel: $60.15 $0.00 CT Qx Amplified DNA Assay on the BD Viper™ XTR/LT Chlamydia trachomatis   87491 Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique   CCI   MUE   NCD $ 35.09 N/A GC Qx Amplified DNA Assay on the BD Viper™ XTR/LT Neisseria gonorrhoeae   87591 Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique   CCI   MUE   NCD $ 35.09 N/A BD Onclarity™ HPV Assay for the BD Viper™ LT and BD COR™ Systems Detection of all high-risk type HPV DNA sequences   87626 Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported high-risk types (eg, 16, 18, 31, 45, 51, 52) and high-risk pooled result(s)   $ 70.20 N/A Becton, Dickinson and Company is not responsible for any actions taken by website users in billing Medicare for Becton, Dickinson and Company products, equipment or devices, including but not limited to, any billing and/or coding errors. Website users rely on the information contained in this website at their own risk and should check with the individual Medicare contractors to verify coverage, coding and payment. The information contained in this website has been compiled by CodeMap, L.L.C. to assist Becton, Dickinson and Company customers. CodeMap, L.L.C. remains solely responsible for its content. The information provided is for general educational purposes only and may not be conclusive or exhaustive. Recent changes in applicable law, regulations and interpretations may not be reflected in the information contained herein. For technical questions, please contact CodeMap at (847) 381-5465. CodeMap® has made every reasonable effort to ensure the accuracy of the information contained on this website. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. CodeMap® makes no representation, warranty, or guarantee that this compilation of Medicare information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors. No part of this web page or data displayed may be redistributed or used without the express written consent of CodeMap®. CPT copyright 2024 American Medical Association. All rights reserved. 02/05/2025 05:53:31 3.144.34.97